CORDIS
EU research results

CORDIS

English EN
Treatment of reperfusion injury using a mitochondrial targeted approach: towards a better understanding of the disease

Treatment of reperfusion injury using a mitochondrial targeted approach: towards a better understanding of the disease

Objective

Current interventional treatment of acute myocardial infarction (AMI) focused on re-establishing cardiac reperfusion has significantly improved clinical outcome by reducing infarct size and mortality due to cardiac ischemia.It is now recognized that events triggered at reperfusion also result in cell death and may account for as much as 50% of the infarct volume, this being termed ischemia-reperfusion injury (IRI). Mitochondrial permeability transition pore (mPTP) opening appears to be a responsible for IRI and a recent small clinical trial with cyclosporine A shows that it is a feasible target for the development of new therapies to treat it. Since total infarct size is a major determinant of a patients risk to develop heart failure, treating IRI is expected to further reduce morbidity, mortality and the need for regenerative medicine following cardiac ischemia. By harnessing a multi-disciplinary consortium of clinical and basic scientists along with four SMEs, MitoCare brings state-of-the art expertise together to 1) better understand IRI pathophysiology and factors directly or indirectly influencing patient’s recovery or response to treatment; 2) investigate the translational usefulness of preclinical models; and 3) compare selected treatments. These objectives will be reached through the following work plan: A) a medium-scale phase II clinical study will evaluate the efficacy of a novel complementary therapy to PCI, the new mPTP modulator TRO40303, while at the same time 1) perform extensive sampling from subjects in the study for analysis of standard and emerging biomarkers; 2) identify confounding factors influencing patients’ outcomes. B) Parallel investigations in preclinical in vitro and in vivo AMI models. C) Statistical analysis of data from clinical and preclinical studies, to identify better diagnostic and prognostic endpoints in man and assess predictive utility of preclinical models.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

TROPHOS SA

Address

Parc Scientifique Luminy Case 931
13288 Marseille Cedex 9

France

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 2 199 952

Administrative Contact

Julien Veys (Mr.)

Participants (16)

Sort alphabetically

Sort by EU Contribution

Expand all

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

France

EU Contribution

€ 536 624

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 278 988

UNIVERSITETET I BERGEN

Norway

EU Contribution

€ 212 512

REGION NORDJYLLAND (NORTH DENMARK REGION)

Denmark

EU Contribution

€ 258 276

LUNDS UNIVERSITET

Sweden

EU Contribution

€ 413 120

REGION HOVEDSTADEN

Denmark

EU Contribution

€ 35 184

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 10 068,11

UNIVERSITY OF BRISTOL

United Kingdom

EU Contribution

€ 272 064

FIRALIS

France

EU Contribution

€ 778 321

GOETEBORGS UNIVERSITET

Sweden

IMACOR AB

Sweden

EU Contribution

€ 299 460

MOBILE HEALTH SAS

France

EU Contribution

€ 113 525,89

OSLO UNIVERSITETSSYKEHUS HF

Norway

EU Contribution

€ 201 530

ODENSE UNIVERSITETSHOSPITAL

Denmark

EU Contribution

€ 206 608

HELSE STAVANGER HF

Norway

EU Contribution

€ 101 052

CENTRE HOSPITALIER REGIONAL DE MARSEILLE ASSISTANCE PUBLIQUE-HOPITAUX MARSEILLE

France

EU Contribution

€ 73 674

Project information

Grant agreement ID: 261034

Status

Closed project

  • Start date

    1 January 2011

  • End date

    31 December 2013

Funded under:

FP7-HEALTH

  • Overall budget:

    € 8 192 211,15

  • EU contribution

    € 5 990 959

Coordinated by:

TROPHOS SA

France